Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
ATRA has been the topic of a number of other reports. BidaskClub lowered shares of Atara Biotherapeutics from a hold rating to a sell rating in a research report on Tuesday, November 13th. Jefferies Financial Group restated a buy rating and issued a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of $47.80.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.13) by ($0.16). Analysts anticipate that Atara Biotherapeutics will post -4.82 earnings per share for the current year.
In other news, CEO Isaac E. Ciechanover sold 7,800 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $40.39, for a total transaction of $315,042.00. Following the transaction, the chief executive officer now directly owns 733,285 shares in the company, valued at $29,617,381.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $41.28, for a total transaction of $61,920.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 97,149 shares of company stock worth $3,753,248. Company insiders own 10.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in ATRA. Principal Financial Group Inc. acquired a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $214,000. Bank of Montreal Can acquired a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $180,000. Amalgamated Bank acquired a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $228,000. TD Asset Management Inc. lifted its position in shares of Atara Biotherapeutics by 4.9% during the second quarter. TD Asset Management Inc. now owns 43,089 shares of the biotechnology company’s stock worth $1,584,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Birchview Capital LP lifted its position in shares of Atara Biotherapeutics by 47.8% during the second quarter. Birchview Capital LP now owns 34,000 shares of the biotechnology company’s stock worth $1,250,000 after purchasing an additional 11,000 shares in the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.